Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today announced the pricing of its initial public offering of 20,000,000 shares of its common stock at a price to the public of $20.00 per share
July 15, 2020
· 2 min read